Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their ...
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is a biotechnology company dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Founded in 2012 and headquartered in Thousand Oaks, California, Atara focuses on developing treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead candidate, tabelecleucel, is in Phase 3 clinical trials ...Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is a biotechnology company dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Founded in 2012 and headquartered in Thousand Oaks, California, Atara focuses on developing treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead candidate, tabelecleucel, is in Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease and other EBV-associated tumors like nasopharyngeal carcinoma. Beyond that, Atara is advancing a robust pipeline of next-generation CAR T immunotherapies for hematologic malignancies and solid tumors, including ATA2271 and ATA3271 (mesothelin-targeting), ATA2431 and ATA3219 (B-cell malignancies), ATA188 for multiple sclerosis, and ATA368 for HPV-related cancers. To enhance R&D, Atara has established collaborations with Memorial Sloan Kettering Cancer Center, QIMR Berghofer Medical Research Institute, and H. Lee Moffitt Cancer Center, as well as a strategic partnership with Bayer AG for mesothelin-targeted CAR T therapies. The company went public in 2014 and is traded on NASDAQ. Financially, Atara has a market cap of approximately $80 million, with a price of $8.94 per share. It reports negative profitability metrics, with a net profit margin of -40.9% and an EBITDA margin of -23.7%, reflecting investment in clinical development. The company has minimal revenue but maintains a strong cash position for its size, with a current ratio of 2.156. Atara's team, led by CEO Cokey Nguyen, includes a workforce that has been significantly reduced to approximately 15 employees following a strategic restructuring. The company's vision is to harness the natural power of T cells to develop off-the-shelf therapies that are accessible and transformative for patients with serious diseases.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$120.8M
-6.3%
+22.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$32.7M
+138.3%
-16.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+82.4%
-1.5%
-8.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
+29.7%
+145.9%
-14.7%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
+27.1%
+140.9%
+4.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-50.9M
+26.1%
-8.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-42.2%
+21.1%
+11.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-137.1%
-204.4%
+1.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.82x
+69.7%
-8.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
